Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4048369 | 0.93 | NPC1 (0.41) | NPC1SIGMAR1ACKR3HPGDTHRB | |
| SCHEMBL4048483 | 0.90 | SIGMAR1 (0.48) | NPC1SIGMAR1ACKR3HPGDTHRB | |
| SCHEMBL4055346 | 0.86 | ACKR3 (0.48) | SIGMAR1ACKR3HPGDMEN1KMT2A | |
| SCHEMBL4052294 | 0.82 | ACKR3 (0.48) | NPC1SIGMAR1ACKR3MEN1KMT2A | |
| SCHEMBL16143480 | 0.81 | SIGMAR1 (0.42) | SIGMAR1ACKR3HPGDTHRBEPHX2 | |
| SCHEMBL207325 | 0.81 | NPC1 (0.49) | NPC1SIGMAR1ACKR3HPGDTHRB | |
| SCHEMBL4054730 | 0.81 | ACKR3 (0.50) | SIGMAR1ACKR3MEN1KMT2AALDH1A1 | |
| SCHEMBL16143615 | 0.80 | ACKR3 (0.48) | ACKR3MEN1KMT2AALDH1A1DRD2 | |
| SCHEMBL4045470 | 0.80 | ACKR3 (0.48) | ACKR3MEN1KMT2AALDH1A1DRD2 | |
| SCHEMBL205370 | 0.79 | SIGMAR1 (0.50) | SIGMAR1HPGDTHRBEPHX2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7476763-B2 | Oxo-substituted cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2009-01-13 | — | — | US | claimed |
| US-20070088034-A1 | Oxo-substituted cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-04-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088034-A1 | Oxo-substituted cyclohexyl-1,4-diamine compounds | AOC1, ODC1, OTC | NPC1 20/4885SIGMAR1 1889/4885ACKR3 3574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.